Solid tumors are abnormal tissue without a liquid area. Most solid tumors are named for the location or type of cell in which they develop, such as breast cancer, prostate cancer, or skin cancer. While solid tumors can be benign, when malignant they are classified as solid tumor cancer.
Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
DATE: June 12, 2020 TIME: 08:00 am PDT, 11:00 am EDT Whole genome imaging using the Saphyr instrument from Bionano detects structural variants (SVs), such as insertions, deletions,...
1. Identify 3 barriers to immune cell response to cancer 2. List 3 approaches to overcome immunosuppressive barriers to bolster the immune response to cancer 3. Explain how fusion proteins c...
B cells have recently come into vogue as important contributors to the anti-tumor immune response in cancer patients. Specifically, B cells and the immune structures in which they reside (te...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently end...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...
The GeoMx Digital Spatial Profiling technology enables high-plex RNA and protein profiling of any region within any tissue type. This workshop will highlight the latest developments toward e...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
DATE: April 14, 2020 TIME: 9:00am PDT, 12:00pm EDT Besides being Gibco Cell Culture Heroes, what do Vivek, Sandra, Daisy, Ameet and Kristine all have in common? They are all stuck at home fo...
DATE: April 2, 2020 TIME: 8:00am PT, 11:00am ET Cyclins A2 and E1 regulate the cell cycle by promoting S phase entry and progression. We recently identified a hepatocellular carcinoma (HCC)...
DATE: March 31, 2020 TIME: 9:00am PT, 12:00pm ET HER2-positive breast cancer is a type of breast cancer caused by over-expression of a protein called human epidermal growth factor receptor 2...
Biomarkers are critical tools for all stages of cancer research, from drug development through clinical applications. Cancer is fundamentally a disease of unregulated cell growth and circumv...
DATE: December 17, 2019TIME: 8:00am PSTMass cytometry instruments simultaneously measure >50 cellular features, with a typical experiment including millions of cells. Dysregulated...
The quest to cure cancer through the manipulation the immune system has been at the forefront of science for the past half-decade. The result has been the emergence of a multitude of promisin...
DATE: September 19, 2019TIME: 9:00am PT, 12:00pm ET Cancer research continues to push the boundaries with new advancements in tissue analysis and biomarker detection. Now, more...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
DATE: June 19, 2019TIME: 8:00am PDT, 11:00am EDT Approximately 80% of all cancers are known to be affected by both somatic mutations and copy number changes. Furthermore, r...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
DATE: June 12, 2020 TIME: 08:00 am PDT, 11:00 am EDT Whole genome imaging using the Saphyr instrument from Bionano detects structural variants (SVs), such as insertions, deletions,...
1. Identify 3 barriers to immune cell response to cancer 2. List 3 approaches to overcome immunosuppressive barriers to bolster the immune response to cancer 3. Explain how fusion proteins c...
B cells have recently come into vogue as important contributors to the anti-tumor immune response in cancer patients. Specifically, B cells and the immune structures in which they reside (te...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently end...
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...
The spread of severe acute respiratory syndrome coronavirus 2 (SARS CoV2), changed the daily life of medical oncologists. To keep safe both patients and healthy workers is the most important...
The GeoMx Digital Spatial Profiling technology enables high-plex RNA and protein profiling of any region within any tissue type. This workshop will highlight the latest developments toward e...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
DATE: April 14, 2020 TIME: 9:00am PDT, 12:00pm EDT Besides being Gibco Cell Culture Heroes, what do Vivek, Sandra, Daisy, Ameet and Kristine all have in common? They are all stuck at home fo...
DATE: April 2, 2020 TIME: 8:00am PT, 11:00am ET Cyclins A2 and E1 regulate the cell cycle by promoting S phase entry and progression. We recently identified a hepatocellular carcinoma (HCC)...
DATE: March 31, 2020 TIME: 9:00am PT, 12:00pm ET HER2-positive breast cancer is a type of breast cancer caused by over-expression of a protein called human epidermal growth factor receptor 2...
Biomarkers are critical tools for all stages of cancer research, from drug development through clinical applications. Cancer is fundamentally a disease of unregulated cell growth and circumv...
DATE: December 17, 2019TIME: 8:00am PSTMass cytometry instruments simultaneously measure >50 cellular features, with a typical experiment including millions of cells. Dysregulated...
The quest to cure cancer through the manipulation the immune system has been at the forefront of science for the past half-decade. The result has been the emergence of a multitude of promisin...
DATE: September 19, 2019TIME: 9:00am PT, 12:00pm ET Cancer research continues to push the boundaries with new advancements in tissue analysis and biomarker detection. Now, more...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
DATE: June 19, 2019TIME: 8:00am PDT, 11:00am EDT Approximately 80% of all cancers are known to be affected by both somatic mutations and copy number changes. Furthermore, r...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
